The Spliceosome: A New Therapeutic Target in Chronic Myeloid Leukaemia

Simple Summary RNA splicing factors are frequently altered in cancer and have been found mutated or deregulated in myeloid malignancies, justifying the growing interest in new therapeutic strategies. We recently showed that the DNA methylation alterations of CD34+CD15− chronic myeloid leukaemia (CML) cells affect alternative splicing genes, suggesting that spliceosome actors might be altered in chronic-phase (CP)-CML. We investigated the expression of 12 splicing genes in primary CP-CML CD34+ cells at diagnosis (n = 15). We found that CP-CML CD34+ cells had a distinct splicing signature profile, suggesting: (i) a spliceosome deregulation from the diagnosis time and (ii) an intraclonal heterogeneity. In vitro incubation of a spliceosome-targeted drug (TG003) showed that CP-CML CD34+ cells are spliceosome dependent; moreover, with the combination of TKI, the two drugs showing an additive effect while sparing healthy donors cells. Our results suggest that the spliceosome may be a new potential target for the treatment of CML. Abstract RNA splicing factors are frequently altered in cancer and can act as both oncoproteins and tumour suppressors. They have been found mutated or deregulated, justifying the growing interest in the targeting of splicing catalysis, splicing regulatory proteins, and/or specific, key altered splicing events. We recently showed that the DNA methylation alterations of CD34+CD15− chronic myeloid leukaemia (CML) cells affect, among others, alternative splicing genes, suggesting that spliceosome actors might be altered in chronic-phase (CP)-CML. We investigated the expression of 12 spliceosome genes known to be oncogenes or tumour suppressor genes in primary CP-CML CD34+ cells at diagnosis (n = 15). We found that CP-CML CD34+ cells had a distinct splicing signature profile as compared with healthy donor CD34+ cells or whole CP-CML cells, suggesting: (i) a spliceosome deregulation from the diagnosis time and (ii) an intraclonal heterogeneity. We could identify three profile types, but there was no relationship with a patient’s characteristics. By incubating cells with TKI and/or a spliceosome-targeted drug (TG003), we showed that CP-CML CD34+ cells are both BCR::ABL and spliceosome dependent, with the combination of the two drugs showing an additive effect while sparing healthy donors cells. Our results suggest that the spliceosome may be a new potential target for the treatment of CML.

[1]  B. Beutler,et al.  Emerging roles of spliceosome in cancer and immunity , 2021, Protein & Cell.

[2]  O. Abdel-Wahab,et al.  U2af1 is required for survival and function of hematopoietic stem/progenitor cells , 2021, Leukemia.

[3]  Jitendra Kumar Meena,et al.  Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer , 2021, Cell.

[4]  B. Eymin.  Targeting the spliceosome machinery: A new therapeutic axis in cancer? , 2020, Biochemical pharmacology.

[5]  Yanmei Xu,et al.  Transcriptome profiling reveals the high incidence of hnRNPA1 exon 8 inclusion in chronic myeloid leukemia , 2020, Journal of advanced research.

[6]  D. Steensma,et al.  Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity. , 2020, Hematology/oncology clinics of North America.

[7]  A. Krainer,et al.  SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia , 2020, Leukemia.

[8]  G. Bressan,et al.  Combined SRPK and AKT pharmacological inhibition is synergistic in T-cell acute lymphoblastic leukemia cells. , 2020, Toxicology in vitro : an international journal published in association with BIBRA.

[9]  Guodong Yang,et al.  Chronic myelogenous leukemia cells remodel the bone marrow niche via exosome-mediated transfer of miR-320 , 2019, Theranostics.

[10]  M. Ladomery,et al.  Autoregulation of the human splice factor kinase CLK1 through exon skipping and intron retention. , 2018, Gene.

[11]  K. Neugebauer,et al.  Blood Relatives: Splicing Mechanisms underlying Erythropoiesis in Health and Disease , 2018, F1000Research.

[12]  P. Cony-Makhoul,et al.  DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+ CD15− cells in early chronic‐phase chronic myeloid leukemia , 2018, Molecular oncology.

[13]  Kenneth C. Anderson,et al.  Protein Arginine Methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in Multiple Myeloma , 2017, Leukemia.

[14]  M. Hagiwara,et al.  Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy , 2017, Scientific Reports.

[15]  A. Toubert,et al.  Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study , 2017, Haematologica.

[16]  D. Vetrie,et al.  The chronic myeloid leukemia stem cell: stemming the tide of persistence. , 2017, Blood.

[17]  D. Vetrie,et al.  CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. , 2017, Blood.

[18]  R. Ren,et al.  Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. , 2016, The Journal of clinical investigation.

[19]  Omar Abdel-Wahab,et al.  Therapeutic targeting of splicing in cancer , 2016, Nature Medicine.

[20]  Eunhee Kim,et al.  RNA splicing factors as oncoproteins and tumour suppressors , 2016, Nature Reviews Cancer.

[21]  Karen Dunn,et al.  Dual targeting of p53 and c-Myc selectively eliminates leukaemic stem cells , 2016, Nature.

[22]  E. Kolaczyk,et al.  MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. , 2016, Cancer letters.

[23]  Y. Akao,et al.  Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells. , 2016, Cancer letters.

[24]  Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 1975;45(3):321-334. , 2016, Blood.

[25]  Richard A. Moore,et al.  Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal , 2015, Proceedings of the National Academy of Sciences.

[26]  Sarah J. Kurley,et al.  The spliceosome is a therapeutic vulnerability in MYC-driven cancer , 2015, Nature.

[27]  M. D. Polêto,et al.  Potential Antileukemia Effect and Structural Analyses of SRPK Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)Isonicotinamide (SRPIN340) , 2015, PloS one.

[28]  Robert A Copeland,et al.  A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. , 2015, Nature chemical biology.

[29]  Y. Akao,et al.  Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia. , 2015, Cancer letters.

[30]  Seishi Ogawa,et al.  PRPF8 Defects Cause Missplicing in Myeloid Malignancies , 2014, Leukemia.

[31]  D. Bates,et al.  Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma , 2014, British Journal of Cancer.

[32]  D. Lane,et al.  Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response , 2014, Cell Death and Differentiation.

[33]  J. Qian,et al.  SF3B1 mutation is a rare event in Chinese patients with acute and chronic myeloid leukemia. , 2013, Clinical biochemistry.

[34]  M. Saville,et al.  p53 is activated in response to disruption of the pre-mRNA splicing machinery , 2013, Oncogene.

[35]  J. Valcárcel,et al.  The spliceosome as a target of novel antitumour drugs , 2012, Nature Reviews Drug Discovery.

[36]  A. Jankowska,et al.  Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. , 2012, Blood.

[37]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[38]  M. Hagiwara,et al.  Chemical treatment enhances skipping of a mutated exon in the dystrophin gene , 2011, Nature communications.

[39]  M. Hagiwara,et al.  Inhibition of Hepatitis C Virus Replication by a Specific Inhibitor of Serine-Arginine-Rich Protein Kinase , 2010, Antimicrobial Agents and Chemotherapy.

[40]  Daniel Becker,et al.  Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication , 2010, Nature.

[41]  M. Assanah,et al.  HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer , 2010, Nature.

[42]  M. Hagiwara,et al.  Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Hiroshi Kimura,et al.  Manipulation of Alternative Splicing by a Newly Developed Inhibitor of Clks* , 2004, Journal of Biological Chemistry.

[44]  S. Salesse,et al.  p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells , 2004, Leukemia.

[45]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[46]  I. Miyoshi,et al.  Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis. , 1983, International journal of cell cloning.

[47]  C. Lozzio,et al.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. , 1975, Blood.

[48]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.